1. Phylogeny  
   Accepted as a member of the casein kinase 1 (CK1) superfamily, tau‐tubulin kinase 1 (TTBK1) is conserved across vertebrate species and is highly restricted in its expression to neuronal tissues in the central nervous system (CNS) (baier2022ck2andprotein pages 3-4). TTBK1 and its paralog TTBK2 share a highly homologous N‐terminal catalytic domain—with approximately 88% sequence identity and 96% similarity—while diverging markedly in their non‐catalytic, regulatory regions (baier2022ck2andprotein pages 27-27, ikezu2014tautubulinkinase pages 1-2). This conservation of the kinase domain positions TTBK1 among an evolutionary core set of serine/threonine kinases that trace their origins to the common ancestor of eukaryotes, even though it is expressed in a very tissue‐restricted manner (ikezu2014tautubulinkinase pages 1-2, bouskila2011ttbk2kinasesubstrate pages 1-2). The evolutionary relationship between TTBK1 and other members of the CK1 superfamily is underscored by the presence of conserved catalytic residues and domain structures typical of serine/threonine kinases, while its distinct CNS‐specific expression distinguishes it from more ubiquitously expressed kinases (baier2022ck2andprotein pages 3-4, liachko2014thetautubulin pages 3-3).
2. Reaction Catalyzed  
   TTBK1 catalyzes the transfer of a phosphate group from ATP to specific serine, threonine, and tyrosine residues on target protein substrates, such as TAU (brain‐derived tau kinase activity) (bao2021mechanismsofregulation pages 1-2, dillon2020acuteinhibitionof pages 1-2). In biochemical terms, the reaction can be formally represented as follows: ATP + [protein]–(L‐serine or L‐threonine) → ADP + [protein]–(L‐serine/threonine)‐phosphate + H⁺ (dillon2020acuteinhibitionof pages 1-2). This enzymatic activity directly results in the conversion of the unphosphorylated substrate protein to its phosphorylated counterpart, an essential modification that underpins the subsequent aggregation and altered function of tau in neurodegenerative conditions (baier2022ck2andprotein pages 26-27).
3. Cofactor Requirements  
   The kinase activity of TTBK1 depends on the presence of divalent metal ions, which serve as essential cofactors for the catalysis of phosphoryl transfer reactions. Experimental evidence indicates that TTBK1 requires Mg²⁺ and/or Mn²⁺ ions for optimal catalytic activity, in line with the typical cofactor requirements of serine/threonine kinases (bouskila2011ttbk2kinasesubstrate pages 4-6, taylor2018pathologicalphosphorylationof pages 13-14). Additionally, the enzyme utilizes ATP as the phosphate donor during its catalytic cycle, and the proper binding of ATP is coordinated in the active site by these metal ions (dillon2020acuteinhibitionof pages 1-2).
4. Substrate Specificity  
   TTBK1 exhibits a distinct substrate specificity that is directed primarily toward tau protein as well as tubulin components of the neuronal cytoskeleton. It phosphorylates TAU on multiple residues including serine 198, serine 199, serine 202, and serine 422, and uniquely phosphorylates tyrosine 197, modifications that are closely linked with the formation of paired helical filaments observed in Alzheimer’s disease and related tauopathies (baier2022ck2andprotein pages 27-27, bao2021mechanismsofregulation pages 1-2). In addition to tau, TTBK1 has been shown to target the RNA‐binding protein TDP-43, a substrate whose phosphorylation contributes to its pathological aggregation in neurodegenerative conditions (dillon2020acuteinhibitionof pages 1-2, ikezu2014tautubulinkinase pages 8-9). While a defined consensus phosphorylation motif for TTBK1 has not been as extensively characterized as for some other kinases, its modification of tau protein at specific serine, threonine, and tyrosine residues underscores a substrate preference that is integral to its biological function (liachko2014thetautubulin pages 3-5).
5. Structure  
   TTBK1 is a large protein consisting of 1321 amino acids, and its domain organization is characterized by an N-terminal catalytic (kinase) domain followed by extensive non-catalytic, regulatory sequences. The N-terminal region, which comprises the kinase domain, contains key structural features including a P-loop (residues approximately 40–49), a DFG motif (typically around residues 176–178) that is essential for coordinating the binding of metal cofactors and ATP, and a flexible activation loop (residues approximately 178–202) (jana2020identificationofhuman pages 1-7). The kinase domain is followed by a regulatory region that includes a distinctive poly-glutamate stretch of about 39 amino acids; this non-catalytic portion is believed to contribute to substrate specificity and may influence the overall conformation of the enzyme (baier2022ck2andprotein pages 2-3, jana2020identificationofhuman pages 1-7). Experimental crystallographic studies and model predictions have provided insight into the three-dimensional structure of TTBK1’s catalytic core, revealing a canonical bilobal kinase fold with a well-defined ATP binding cleft and conserved catalytic residues necessary for phosphoryl transfer (jana2020identificationofhuman pages 1-7, baier2022ck2andprotein pages 3-4). Although no complete high-resolution structure of the full-length protein has been published, the available structural data support the presence of regulatory motifs and characteristic kinase structural elements such as the C-helix and hydrophobic spine that are common to serine/threonine kinases (baier2022ck2andprotein pages 3-4, ikezu2014tautubulinkinase pages 8-9).
6. Regulation  
   TTBK1 activity is modulated by several regulatory mechanisms that include autophosphorylation and post-translational modifications. The enzyme undergoes extensive auto-phosphorylation, with studies reporting the identification of multiple autophosphorylation sites that directly influence its catalytic efficiency (bao2021mechanismsofregulation pages 10-11, bao2021mechanismsofregulation pages 5-7). These auto-phosphorylation events occur within both the kinase domain and adjacent regulatory regions, thereby affecting the protein’s conformation and substrate accessibility without the need for additional external kinases (bao2021mechanismsofregulation pages 10-11). In cellular models, knockdown studies have confirmed that modulation of TTBK1 expression levels directly correlates with altered phosphorylation of tau at the pathological Ser422 site, a key readout of its activity (bao2021mechanismsofregulation pages 1-2, dillon2020acuteinhibitionof pages 1-2). In addition to auto-phosphorylation, small molecule inhibitors have been shown to effectively reduce TTBK1 catalytic activity in both biochemical and cell-based assays, providing further evidence that phosphorylation events are central to the regulation of TTBK1 function (dillon2020acuteinhibitionof pages 11-12, halkina2021discoveryofpotent pages 1-2). The regulation of TTBK1 through these post-translational modifications is critical for maintaining the balance of tau phosphorylation in neuronal cells (bao2021mechanismsofregulation pages 2-4).
7. Function  
   TTBK1 is a neuron-specific serine/threonine kinase that plays an essential role in the phosphorylation of tau protein, thereby inducing tau aggregation and facilitating the formation of neurofibrillary tangles characteristic of Alzheimer’s disease and related tauopathies (baier2022ck2andprotein pages 26-27, dillon2020acuteinhibitionof pages 1-2). Its expression is predominantly confined to the brain, with high levels detected in the adult cortex, hippocampus, and cerebellum (baier2022ck2andprotein pages 3-4, ikezu2014tautubulinkinase pages 1-2). Through the phosphorylation of tau at multiple sites—including serines 198, 199, 202, and 422 and tyrosine 197—TTBK1 modulates tau’s microtubule binding and promotes its aggregation into pathological structures (baier2022ck2andprotein pages 27-27, bao2021mechanismsofregulation pages 1-2). In addition to tau, TTBK1 phosphorylates TDP-43, a modification that is associated with its cytoplasmic accumulation and aggregation in neurodegenerative diseases (dillon2020acuteinhibitionof pages 1-2, ikezu2014tautubulinkinase pages 8-9). The downstream effects of TTBK1 activity include disruptions in microtubule stability, alterations in neurite dynamics, and impairments in synaptic signaling, all of which contribute to the neurodegenerative process (yukawa2023antisenseoligonucleotidebasedtargeting pages 10-11, mcmillan2020adultonsetpanneuronal pages 14-15). The enzyme is thus regarded as a critical mediator in tauopathies due to its ability to trigger pathological phosphorylation events that compromise neuronal integrity (baier2022ck2andprotein pages 26-27, dillon2020acuteinhibitionof pages 1-2).
8. Other Comments  
   TTBK1 is alternatively known as brain‐derived tau kinase and is a target of substantial therapeutic interest in the context of neurodegenerative disorders given its central role in tau phosphorylation and aggregation (Information). Recent studies have identified potent, brain-penetrant small molecule inhibitors such as BIIB-TTBK1i that exhibit nanomolar potency and significant selectivity, effectively reducing tau phosphorylation at disease-relevant sites in preclinical models (dillon2020acuteinhibitionof pages 11-12, halkina2021discoveryofpotent pages 1-2). Genetic studies have further associated variants in the TTBK1 gene with modified risk or altered age at onset of Alzheimer’s disease, thereby linking its kinase activity to the pathogenesis of tauopathies (ikezu2014tautubulinkinase pages 1-2, taylor2018pathologicalphosphorylationof pages 1-2). In addition, TTBK1 has been implicated in the phosphorylation of TDP-43, a protein whose aberrant aggregation is a hallmark of frontotemporal lobar degeneration (FTLD) (liachko2014thetautubulinkinase pages 3-5). The combination of its CNS-specific expression and its discrete substrate specificity underscores the therapeutic potential of targeting TTBK1 in neurodegenerative disease, while its structural features render its active site amenable to structure-based inhibitor design (jana2020identificationofhuman pages 30-31, dillon2020acuteinhibitionof pages 8-9).
9. References  
   Baier, A. & Szyszka, R. (2022). Ck2 and protein kinases of the ck1 superfamily as targets for neurodegenerative disorders. Frontiers in Molecular Biosciences, Oct 2022, pages 26-27; pages 27-27; pages 3-4; pages 2-3; pages 22-23.  
   Bao, C. et al. (2021). Mechanisms of regulation and diverse activities of tau-tubulin kinase (ttbk) isoforms. Cellular and Molecular Neurobiology, May 2021, pages 1-2; pages 10-11; pages 2-4; pages 5-7; pages 8-10.  
   Bouskila, M. et al. (2011). Ttbk2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development. The Biochemical Journal, Jul 2011, pages 1-2; pages 2-4; pages 4-6; pages 7-9.  
   Dillon, G.M. et al. (2020). Acute inhibition of the cns-specific kinase ttbk1 significantly lowers tau phosphorylation at several disease relevant sites. PLOS ONE, Apr 2020, pages 1-2; pages 11-12; pages 12-14; pages 2-4; pages 4-6; pages 6-8; pages 8-9.  
   Halkina, T. et al. (2021). Discovery of potent and brain-penetrant tau tubulin kinase 1 (ttbk1) inhibitors that lower tau phosphorylation in vivo. Journal of Medicinal Chemistry, May 2021, pages 1-2.  
   Ikezu, S. & Ikezu, T. (2014). Tau-tubulin kinase. Frontiers in Molecular Neuroscience, Apr 2014, pages 1-2; pages 3-5; pages 8-9; pages 9-10.  
   Jana, S. & Singh, S.K. (2020). Identification of human tau-tubulin kinase 1 inhibitors: an integrated e-pharmacophore-based virtual screening and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, Apr 2020, pages 1-7; pages 30-31.  
   Liachko, N.F. et al. (2014). The tau tubulin kinases ttbk1/2 promote accumulation of pathological tdp-43. PLoS Genetics, Dec 2014, pages 2-3; pages 3-3; pages 3-5.  
   Taylor, L.M. et al. (2018). Pathological phosphorylation of tau and tdp-43 by ttbk1 and ttbk2 drives neurodegeneration. Molecular Neurodegeneration, Feb 2018, pages 1-2; pages 10-12; pages 13-14.  
   Yukawa, K. et al. (2023). Antisense oligonucleotide-based targeting of tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in ps19 tauopathy mice. Acta Neuropathologica Communications, Oct 2023, pages 10-11; pages 11-12.  
   McMillan, P.J. et al. (2020). Adult onset pan-neuronal human tau tubulin kinase 1 expression causes severe cerebellar neurodegeneration in mice. Acta Neuropathologica Communications, Nov 2020, pages 14-15.

References

1. (baier2022ck2andprotein pages 26-27): Andrea Baier and Ryszard Szyszka. Ck2 and protein kinases of the ck1 superfamily as targets for neurodegenerative disorders. Frontiers in Molecular Biosciences, Oct 2022. URL: https://doi.org/10.3389/fmolb.2022.916063, doi:10.3389/fmolb.2022.916063. This article has 14 citations and is from a peer-reviewed journal.
2. (baier2022ck2andprotein pages 27-27): Andrea Baier and Ryszard Szyszka. Ck2 and protein kinases of the ck1 superfamily as targets for neurodegenerative disorders. Frontiers in Molecular Biosciences, Oct 2022. URL: https://doi.org/10.3389/fmolb.2022.916063, doi:10.3389/fmolb.2022.916063. This article has 14 citations and is from a peer-reviewed journal.
3. (baier2022ck2andprotein pages 3-4): Andrea Baier and Ryszard Szyszka. Ck2 and protein kinases of the ck1 superfamily as targets for neurodegenerative disorders. Frontiers in Molecular Biosciences, Oct 2022. URL: https://doi.org/10.3389/fmolb.2022.916063, doi:10.3389/fmolb.2022.916063. This article has 14 citations and is from a peer-reviewed journal.
4. (bao2021mechanismsofregulation pages 1-2): Channa Bao, Bekim Bajrami, Douglas J. Marcotte, Jayanth V. Chodaparambil, Hannah M. Kerns, Jaclyn Henderson, Ru Wei, Benbo Gao, and Gregory M. Dillon. Mechanisms of regulation and diverse activities of tau-tubulin kinase (ttbk) isoforms. Cellular and Molecular Neurobiology, 41:669-685, May 2021. URL: https://doi.org/10.1007/s10571-020-00875-6, doi:10.1007/s10571-020-00875-6. This article has 21 citations and is from a peer-reviewed journal.
5. (bao2021mechanismsofregulation pages 10-11): Channa Bao, Bekim Bajrami, Douglas J. Marcotte, Jayanth V. Chodaparambil, Hannah M. Kerns, Jaclyn Henderson, Ru Wei, Benbo Gao, and Gregory M. Dillon. Mechanisms of regulation and diverse activities of tau-tubulin kinase (ttbk) isoforms. Cellular and Molecular Neurobiology, 41:669-685, May 2021. URL: https://doi.org/10.1007/s10571-020-00875-6, doi:10.1007/s10571-020-00875-6. This article has 21 citations and is from a peer-reviewed journal.
6. (bao2021mechanismsofregulation pages 2-4): Channa Bao, Bekim Bajrami, Douglas J. Marcotte, Jayanth V. Chodaparambil, Hannah M. Kerns, Jaclyn Henderson, Ru Wei, Benbo Gao, and Gregory M. Dillon. Mechanisms of regulation and diverse activities of tau-tubulin kinase (ttbk) isoforms. Cellular and Molecular Neurobiology, 41:669-685, May 2021. URL: https://doi.org/10.1007/s10571-020-00875-6, doi:10.1007/s10571-020-00875-6. This article has 21 citations and is from a peer-reviewed journal.
7. (bouskila2011ttbk2kinasesubstrate pages 1-2): M. Bouskila, Noor Esoof, L. Gay, Emily Fang, M. Deák, M. Begley, L. Cantley, A. Prescott, K. Storey, and D. Alessi. Ttbk2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development. The Biochemical journal, 437 1:157-67, Jul 2011. URL: https://doi.org/10.1042/bj20110276, doi:10.1042/bj20110276. This article has 68 citations.
8. (dillon2020acuteinhibitionof pages 1-2): Gregory M. Dillon, Jaclyn L. Henderson, Channa Bao, John A. Joyce, Michael Calhoun, Brenda Amaral, Kristopher W. King, Bekim Bajrami, and Dania Rabah. Acute inhibition of the cns-specific kinase ttbk1 significantly lowers tau phosphorylation at several disease relevant sites. PLOS ONE, 15:e0228771, Apr 2020. URL: https://doi.org/10.1371/journal.pone.0228771, doi:10.1371/journal.pone.0228771. This article has 26 citations and is from a peer-reviewed journal.
9. (dillon2020acuteinhibitionof pages 11-12): Gregory M. Dillon, Jaclyn L. Henderson, Channa Bao, John A. Joyce, Michael Calhoun, Brenda Amaral, Kristopher W. King, Bekim Bajrami, and Dania Rabah. Acute inhibition of the cns-specific kinase ttbk1 significantly lowers tau phosphorylation at several disease relevant sites. PLOS ONE, 15:e0228771, Apr 2020. URL: https://doi.org/10.1371/journal.pone.0228771, doi:10.1371/journal.pone.0228771. This article has 26 citations and is from a peer-reviewed journal.
10. (halkina2021discoveryofpotent pages 1-2): Tamara Halkina, Jaclyn L. Henderson, Edward Y. Lin, Martin K. Himmelbauer, J. Howard Jones, Marta Nevalainen, Jun Feng, Kristopher King, Michael Rooney, Joshua L. Johnson, Douglas J. Marcotte, Jayanth V. Chodaparambil, P. Rajesh Kumar, Thomas A. Patterson, Paramasivam Murugan, Eli Schuman, LaiYee Wong, Thomas Hesson, Sarah Lamore, Channa Bao, Michael Calhoun, Hannah Certo, Brenda Amaral, Gregory M. Dillon, Rab Gilfillan, and Felix Gonzalez-Lopez de Turiso. Discovery of potent and brain-penetrant tau tubulin kinase 1 (ttbk1) inhibitors that lower tau phosphorylation in vivo. Journal of Medicinal Chemistry, 64:6358-6380, May 2021. URL: https://doi.org/10.1021/acs.jmedchem.1c00382, doi:10.1021/acs.jmedchem.1c00382. This article has 29 citations and is from a highest quality peer-reviewed journal.
11. (ikezu2014tautubulinkinase pages 1-2): Seiko Ikezu and Tsuneya Ikezu. Tau-tubulin kinase. Frontiers in Molecular Neuroscience, Apr 2014. URL: https://doi.org/10.3389/fnmol.2014.00033, doi:10.3389/fnmol.2014.00033. This article has 81 citations and is from a peer-reviewed journal.
12. (ikezu2014tautubulinkinase pages 8-9): Seiko Ikezu and Tsuneya Ikezu. Tau-tubulin kinase. Frontiers in Molecular Neuroscience, Apr 2014. URL: https://doi.org/10.3389/fnmol.2014.00033, doi:10.3389/fnmol.2014.00033. This article has 81 citations and is from a peer-reviewed journal.
13. (jana2020identificationofhuman pages 1-7): Srabanti Jana and Sushil Kumar Singh. Identification of human tau-tubulin kinase 1 inhibitors: an integrated e-pharmacophore-based virtual screening and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, 38:886-900, Apr 2020. URL: https://doi.org/10.1080/07391102.2019.1590242, doi:10.1080/07391102.2019.1590242. This article has 11 citations and is from a peer-reviewed journal.
14. (jana2020identificationofhuman pages 30-31): Srabanti Jana and Sushil Kumar Singh. Identification of human tau-tubulin kinase 1 inhibitors: an integrated e-pharmacophore-based virtual screening and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, 38:886-900, Apr 2020. URL: https://doi.org/10.1080/07391102.2019.1590242, doi:10.1080/07391102.2019.1590242. This article has 11 citations and is from a peer-reviewed journal.
15. (yukawa2023antisenseoligonucleotidebasedtargeting pages 10-11): Kayo Yukawa, Satomi Yamamoto-Mcguire, Louis Cafaro, Christine Hong, Fredrik Kamme, Tsuneya Ikezu, and Seiko Ikezu. Antisense oligonucleotide-based targeting of tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in ps19 tauopathy mice. Acta Neuropathologica Communications, Oct 2023. URL: https://doi.org/10.1186/s40478-023-01661-3, doi:10.1186/s40478-023-01661-3. This article has 5 citations and is from a peer-reviewed journal.
16. (baier2022ck2andprotein pages 2-3): Andrea Baier and Ryszard Szyszka. Ck2 and protein kinases of the ck1 superfamily as targets for neurodegenerative disorders. Frontiers in Molecular Biosciences, Oct 2022. URL: https://doi.org/10.3389/fmolb.2022.916063, doi:10.3389/fmolb.2022.916063. This article has 14 citations and is from a peer-reviewed journal.
17. (bao2021mechanismsofregulation pages 5-7): Channa Bao, Bekim Bajrami, Douglas J. Marcotte, Jayanth V. Chodaparambil, Hannah M. Kerns, Jaclyn Henderson, Ru Wei, Benbo Gao, and Gregory M. Dillon. Mechanisms of regulation and diverse activities of tau-tubulin kinase (ttbk) isoforms. Cellular and Molecular Neurobiology, 41:669-685, May 2021. URL: https://doi.org/10.1007/s10571-020-00875-6, doi:10.1007/s10571-020-00875-6. This article has 21 citations and is from a peer-reviewed journal.
18. (bouskila2011ttbk2kinasesubstrate pages 4-6): M. Bouskila, Noor Esoof, L. Gay, Emily Fang, M. Deák, M. Begley, L. Cantley, A. Prescott, K. Storey, and D. Alessi. Ttbk2 kinase substrate specificity and the impact of spinocerebellar-ataxia-causing mutations on expression, activity, localization and development. The Biochemical journal, 437 1:157-67, Jul 2011. URL: https://doi.org/10.1042/bj20110276, doi:10.1042/bj20110276. This article has 68 citations.
19. (dillon2020acuteinhibitionof pages 8-9): Gregory M. Dillon, Jaclyn L. Henderson, Channa Bao, John A. Joyce, Michael Calhoun, Brenda Amaral, Kristopher W. King, Bekim Bajrami, and Dania Rabah. Acute inhibition of the cns-specific kinase ttbk1 significantly lowers tau phosphorylation at several disease relevant sites. PLOS ONE, 15:e0228771, Apr 2020. URL: https://doi.org/10.1371/journal.pone.0228771, doi:10.1371/journal.pone.0228771. This article has 26 citations and is from a peer-reviewed journal.
20. (liachko2014thetautubulin pages 3-3): Nicole F. Liachko, Pamela J. McMillan, Timothy J. Strovas, Elaine Loomis, Lynne Greenup, Jill R. Murrell, Bernardino Ghetti, Murray A. Raskind, Thomas J. Montine, Thomas D. Bird, James B. Leverenz, and Brian C. Kraemer. The tau tubulin kinases ttbk1/2 promote accumulation of pathological tdp-43. PLoS Genetics, 10:e1004803, Dec 2014. URL: https://doi.org/10.1371/journal.pgen.1004803, doi:10.1371/journal.pgen.1004803. This article has 130 citations and is from a domain leading peer-reviewed journal.
21. (liachko2014thetautubulin pages 3-5): Nicole F. Liachko, Pamela J. McMillan, Timothy J. Strovas, Elaine Loomis, Lynne Greenup, Jill R. Murrell, Bernardino Ghetti, Murray A. Raskind, Thomas J. Montine, Thomas D. Bird, James B. Leverenz, and Brian C. Kraemer. The tau tubulin kinases ttbk1/2 promote accumulation of pathological tdp-43. PLoS Genetics, 10:e1004803, Dec 2014. URL: https://doi.org/10.1371/journal.pgen.1004803, doi:10.1371/journal.pgen.1004803. This article has 130 citations and is from a domain leading peer-reviewed journal.
22. (mcmillan2020adultonsetpanneuronal pages 14-15): Pamela McMillan, Jeanna Wheeler, Rachel E. Gatlin, Laura Taylor, Tim Strovas, Misa Baum, Thomas D. Bird, Caitlin Latimer, C. Dirk Keene, Brian C. Kraemer, and Nicole F. Liachko. Adult onset pan-neuronal human tau tubulin kinase 1 expression causes severe cerebellar neurodegeneration in mice. Acta Neuropathologica Communications, Nov 2020. URL: https://doi.org/10.1186/s40478-020-01073-7, doi:10.1186/s40478-020-01073-7. This article has 9 citations and is from a peer-reviewed journal.
23. (taylor2018pathologicalphosphorylationof pages 1-2): Laura M. Taylor, Pamela J. McMillan, Nicole F. Liachko, Timothy J. Strovas, Bernardino Ghetti, Thomas D. Bird, C. Dirk Keene, and Brian C. Kraemer. Pathological phosphorylation of tau and tdp-43 by ttbk1 and ttbk2 drives neurodegeneration. Molecular Neurodegeneration, Feb 2018. URL: https://doi.org/10.1186/s13024-018-0237-9, doi:10.1186/s13024-018-0237-9. This article has 93 citations and is from a highest quality peer-reviewed journal.
24. (taylor2018pathologicalphosphorylationof pages 13-14): Laura M. Taylor, Pamela J. McMillan, Nicole F. Liachko, Timothy J. Strovas, Bernardino Ghetti, Thomas D. Bird, C. Dirk Keene, and Brian C. Kraemer. Pathological phosphorylation of tau and tdp-43 by ttbk1 and ttbk2 drives neurodegeneration. Molecular Neurodegeneration, Feb 2018. URL: https://doi.org/10.1186/s13024-018-0237-9, doi:10.1186/s13024-018-0237-9. This article has 93 citations and is from a highest quality peer-reviewed journal.